Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma

Table 3 Patients at risk for recurrence or death at successive follow-up times

Patients at risk for recurrence
years	0	1	2	3	4	5	6	7	8	9	10	11	12
GP88 < 3+	217	213	199	187	170	142	111	88	62	38	29	21	11
GP88 = 3+	47	44	41	33	25	19	12	8	4	2	1	0	0
Patients at risk for death
years	0	1	2	3	4	5	6	7	8	9	10	11	12
GP88 < 3+	217	214	201	192	178	148	120	9	66	42	30	22	11
GP88 = 3+	47	46	44	37	31	25	18	13	6	2	1	0	0

The data show the number of patients at risk for recurrence or death at 12-month intervals out to 12 years following initial diagnosis in the two GP88 groups (GP88 < 3+ and GP88+3+) in the validation study. The maximum follow-up was 122 months in the GP88 = 3+ group and 205 months in the GP88 < 3+ group,

ISSN: 1465-542X